Tryptase, a serine protease stored and released from mast cells (MCs) granules has been identified as a new non-classical angiogenetic factor and it is an agonist of the proteinase-activated receptor-2 (PAR-2).Published in vitro data suggest that tryptase may increase capillary growth and endothelial cell proliferation by activation of PAR-2. According to these data we shown that MCDPT, PAR-2 and MVD paralleled to each other suggesting a role in in vivo breast cancer angiogenesis. In this context several tryptase inhibitors such as gabexate mesilate and nafamostat mesilate might be evaluated in clinical trials as a new antiangiogenetic drugs.
TRYPTASE AND PROTEASE-ACTIVATED RECEPTOR-2 EXPRESSION PARALLELED WITH MICROVASCULAR DENSITY IN BREAST CANCER PATIENTS
ZIZZO, Nicola;
2010-01-01
Abstract
Tryptase, a serine protease stored and released from mast cells (MCs) granules has been identified as a new non-classical angiogenetic factor and it is an agonist of the proteinase-activated receptor-2 (PAR-2).Published in vitro data suggest that tryptase may increase capillary growth and endothelial cell proliferation by activation of PAR-2. According to these data we shown that MCDPT, PAR-2 and MVD paralleled to each other suggesting a role in in vivo breast cancer angiogenesis. In this context several tryptase inhibitors such as gabexate mesilate and nafamostat mesilate might be evaluated in clinical trials as a new antiangiogenetic drugs.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
